EpiEndo Pharmaceuticals is pleased to be celebrating its 10-year anniversary today.

REYKJAVIK, ICELAND – 2 November 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has initiated a healthy volunteer drug-drug interaction (DDI) clinical trial for lead compound, EP395.

REYKJAVIK, ICELAND – 23 October 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, has completed its proof of pharmacology study for lead asset EP395 in healthy volunteers.

REYKJAVIK, ICELAND - 23 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, has contributed to a chapter in a key medical textbook, published this month.

REYKJAVIK, ICELAND - 16 August 2023 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic airway diseases, will have data presented in three abstracts at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

EpiEndo Pharmaceuticals announces that CEO, Maria Bech, and CFO, Stefán Pétursson, will be attending the BIO International Convention from June 5-8 at the Boston Convention & Exhibition Center in Boston, Massachusetts.

EpiEndo Pharmaceuticals has appointed Dr Kate Hanrott as Director of Clinical Operations and Sciences, with immediate effect.

SCIENCE4PEACE is a unique manifestation of the Swedish - American Life Science Summit (SALSS) together with The Galien Foundation, taking place in Stockholm, Sweden on the 12th of December during the Nobel festivities.

EpiEndo Pharmaceuticals has received regulatory approval to commence a Phase 2a clinical trial with lead molecule EP395 in COPD (Chronic Obstructive Pulmonary Disease) patients.